Last reviewed · How we verify

Psoriatic Arthritis — Treatment Landscape & Competitive Intelligence

Psoriatic Arthritis (Immunology & Inflammation) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Immunology & Inflammation 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Psoriatic Arthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Skyrizi RISANKIZUMAB AbbVie Interleukin-23 Antagonist [EPC] Interleukin-23 subunit alpha 2019-01-01
Taltz ixekizumab Eli Lilly Interleukin-17A antagonist Interleukin 17A (IL-17A) cytokine 2016-01-01
Cosentyx secukinumab Novartis IL-17A antagonist Interleukin-17A (IL-17A) 2015-01-01
Xeljanz Tofacitinib Citrate Pfizer JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
Xeljanz tofacitinib Pfizer JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
Cimzia CERTOLIZUMAB PEGOL UCB Tumor Necrosis Factor Blocker [EPC] TNFα 2008-01-01
Abrilada Adalimumab-Afzb AbbVie TNF blocker Tumor necrosis factor-alpha (TNF-alpha) 2002-01-01
Humira ADALIMUMAB AbbVie TNF blocker Tumor Necrosis Factor-alpha (TNF-alpha) 2002-01-01
Trexall methotrexate Generic (originally Lederle Laboratories) Antifolate, DMARD Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 1953-12-07
Humira Humira Sohag University Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 9 drugs in Psoriatic Arthritis
  2. AbbVie · 3 drugs in Psoriatic Arthritis
  3. Biocad · 1 drug in Psoriatic Arthritis
  4. Eli Lilly · 1 drug in Psoriatic Arthritis
  5. Generic (originally Lederle Laboratories) · 1 drug in Psoriatic Arthritis
  6. Janssen Research & Development, LLC · 1 drug in Psoriatic Arthritis
  7. Novartis · 1 drug in Psoriatic Arthritis
  8. Sohag University · 1 drug in Psoriatic Arthritis
  9. UCB · 1 drug in Psoriatic Arthritis
  10. University of Washington · 1 drug in Psoriatic Arthritis
  11. · 1 drug in Psoriatic Arthritis
  12. Yale University · 1 drug in Psoriatic Arthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Psoriatic Arthritis:

Cite this brief

Drug Landscape (2026). Psoriatic Arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/psoriatic-arthritis. Accessed 2026-05-16.

Related